Skip to main content
. Author manuscript; available in PMC: 2022 May 12.
Published in final edited form as: Pharm Res. 2021 May 12;38(5):803–817. doi: 10.1007/s11095-021-03046-4

Fig. 1:

Fig. 1:

(A) Structures of NL-1 and pioglitazone (B) The mitoNEET ligand NL-1 does not activate PPAR-gamma receptor. The positive control rosiglitazone had significantly higher bioluminescence activity compared to control and NL-1 (P<0.05) N = 4. (C) NL-1 at 10 mg/kg did not lower blood glucose after glucose tolerance test. Each data point represents mean ± S.D. where N = 4.